Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Locoregional therapy

3 evidence topics · 2 sources

Guideline recommendations for ablation, stereotactic radiotherapy, and intra-arterial therapy

“Local ablation could be considered as an option for patients with iCCA ≤3 cm who have contraindications or are otherwise unfit for surgery [III, B]” (opens the source at this quote in a new tab)

“SBRT can be considered for patients with iCCA in case of contraindication to surgery for liver-limited disease in the palliative setting [III, C]” (opens the source at this quote in a new tab)

“Intraarterial therapies, in combination with systemic ChT, can be an option for patients with liver-limited iCCA and discussed by the MDTB according to local availability [III, C]” (opens the source at this quote in a new tab)

Hepatic artery infusion pump chemotherapy: pooled analysis of four phase 2 trials

“Systemic therapy is the standard of care for unresectable intrahepatic cholangiocarcinoma (iCCA), but overall survival (OS) remains poor.” (opens the source at this quote in a new tab)

“The pooled median OS was 26 months (95% CI 22-30), with 3-year and 5-year OS rates of 28% (95% CI 22-37) and 15% (95% CI 10-23), respectively.” (opens the source at this quote in a new tab)

“Hepatic artery infusion pump (HAIP) chemotherapy with floxuridine (FUDR) has been shown to prolong survival but is limited to expert centers.” (opens the source at this quote in a new tab)

“Liver-confined disease was defined as absence of extrahepatic metastatic disease, although locoregional lymph node metastases were allowed in the two most recent trials.” (opens the source at this quote in a new tab)

Hepatic artery infusion pump chemotherapy: pump implantation complications and biliary sclerosis

“Twenty patients (14%) had major postoperative complications following pump implantation requiring reintervention. Three patients (2%) developed ascites, which was treated with percutaneous drainage.” (opens the source at this quote in a new tab)

“Biliary sclerosis, a long-term complication associated with HAIP chemotherapy with FUDR, necessitated biliary stenting in two patients (1.4%).” (opens the source at this quote in a new tab)